Liaoning He Eye Hospital Group (301103.SZ) shareholder Advanced Manufacturing Fund intends to reduce its shareholding by no more than 1.97%
He Eye Hospital (301103.SZ) announced that the company's shareholder Advanced Manufacturing Industry Investment Fund (Limited Partnership) (referred to as "Advanced Manufacturing Fund") plans to reduce its total holdings of the company's shares through centralized bidding and block trading on the stock exchange from February 7, 2026 to May 6, 2026 by no more than 3,106,074 shares, accounting for 1.97% of the company's total share capital (2% of the total share capital excluding the number of shares in the repurchase special account).
Liaoning He Eye Hospital Group (301103.SZ) announcement that the company's shareholder Advanced Manufacturing Industry Investment Fund (Limited Partnership) (referred to as "Advanced Manufacturing Fund") plans to reduce its total holding of the company's shares by no more than 310,607.4 shares, or 1.97% of the total share capital, through centralized bidding and block trading on the securities exchange from February 7th, 2026 to May 6th, 2026. This represents 2% of the total share capital excluding the shares held in the company's repurchase special account.
Related Articles
CHINA RUYI (00136) intends to invest approximately 14.2 million US dollars in AIsphere to explore innovative applications of artificial intelligence technology in the production and operation of film, streaming media, and game content businesses.
Huaren Biology-B (02396): The stable price period has ended, no stable pricing actions, and the oversubscription rights have expired.
REFIRE (02570) intends to offer approximately 18.01% discount on the placement of 4.536 million shares, raising around HK$258 million in net proceeds.
CHINA RUYI (00136) intends to invest approximately 14.2 million US dollars in AIsphere to explore innovative applications of artificial intelligence technology in the production and operation of film, streaming media, and game content businesses.
Huaren Biology-B (02396): The stable price period has ended, no stable pricing actions, and the oversubscription rights have expired.
REFIRE (02570) intends to offer approximately 18.01% discount on the placement of 4.536 million shares, raising around HK$258 million in net proceeds.
